In recent years, the quest for effective treatments and supplements that can aid cognitive function has captured the attention of both researchers and healthcare enthusiasts. The exploration of natural compounds continues to hold promise, with various dietary supplements emerging for their potential neuroprotective properties. A groundbreaking study has been conducted by a team of scientists, including Aboubaker, D.H., Elsayed, A.A.A., and El-Gohary, A., titled “Author Correction: Introduction of Cistanche phelypaea fatty acids as a new natural neurotrophic supplement by evaluating its effects in normal and Alzheimer’s diseased rats.” This significant research delves into the therapeutic potential of Cistanche phelypaea, an herb long recognized in traditional medicine, regarded for its supposed cognitive-enhancing properties.

Cistanche phelypaea, a member of the Orobanchaceae family, has garnered interest due to its unique bioactive compounds, particularly fatty acids, that are believed to play a crucial role in cellular health and cognitive function. The herb has been used in traditional Asian medicine, yet its systematic exploration within modern scientific contexts is still emerging. The current investigation evaluates how these fatty acids may function as neurotrophic supplements, providing the necessary support for neuronal health and regeneration.

Neurotrophic factors are essential for the growth, survival, and differentiation of neurons. They are critical players in the maintenance of brain health, and their deficiency is often linked to neurodegenerative diseases such as Alzheimer’s. In this study, the authors sought to determine whether Cistanche phelypaea could enhance the presence or activity of these neurotrophic factors, ultimately leading to improved cognitive function in both normal conditions and in the presence of Alzheimer’s pathology.

To conduct their research, the team utilized an animal model, deploying both healthy and Alzheimer’s diseased rats in a series of behavioral and biochemical assays. The choice of rats as their model organism allowed for sufficient ethical flexibility while providing reliable insights into mammalian biology. Through rigorous experimentation, they could glean data on how the administration of Cistanche phelypaea fatty acids influenced cognitive performance and neurochemical markers associated with brain health.

One of the standout results from this research was a marked improvement in cognitive performance among the rats that received the fatty acids. The researchers employed a series of mazes and memory tasks to assess the cognitive abilities of the subjects. Rats administered with Cistanche phelypaea showed enhanced memory recall and spatial navigation abilities compared to those in the control group. Such findings are critical as they suggest that the fatty acids could counteract cognitive decline, especially in the context of Alzheimer’s disease.

Biochemical analyses further substantiated the behavioral results. Blood samples and brain tissues were examined for changes in levels of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF), which is crucial for synaptic plasticity and overall brain function. The study reported elevated levels of BDNF in the brain tissues of treated rats, indicating that Cistanche phelypaea may indeed facilitate neuroprotection and neurogenesis. This biochemical support complements the observed behavioral improvement, suggesting a dual mechanism at play.

The implications of this study extend far beyond the laboratory. As the global population ages, the incidence of neurodegenerative diseases is projected to rise significantly. The quest for effective treatments has become an urgent priority on the public health front. The results from Aboubaker et al.’s research open new avenues for exploring natural therapies and encourage further investigation into plant-based compounds that can contribute positively to brain health.

Moreover, the research also highlights the importance of revisiting traditional herbal practices through the lens of modern science. Cistanche phelypaea’s long-standing use in traditional medicine can inform contemporary clinical applications, bridging the gap between ancient wisdom and scientific validation. This study thus not only reinforces the value of natural products but also emphasizes the need for rigorous scientific investigation into herbal medicine.

As the scientific community continues to investigate potential solutions to combat cognitive decline, this study serves as a beacon of hope. With natural neurotrophic supplements like Cistanche phelypaea gaining recognition, there may soon be viable alternatives to synthetic drugs that often come with a myriad of side effects. The positive results from this research underscore the necessity for continued exploration of botanical compounds that hold promise for brain health.

Furthermore, this exploration is particularly timely given the rising interest in personalized medicine and wellness. Many individuals are actively seeking natural supplements to improve their cognitive performance, enhance memory, or support overall brain health. As interest flourishes in this area, studies like this one contribute valuable knowledge that aids consumers in making informed choices about their health.

However, it is essential to approach this emerging field with a balanced perspective. While the potential benefits of Cistanche phelypaea are promising, there remains a need for thorough clinical trials in humans before establishing definitive efficacy and safety profiles. The research team acknowledges that more extensive studies are required to ascertain optimal dosages and long-term effects, ensuring that the transition from animal models to human applications is safely navigated.

In conclusion, the work of Aboubaker and colleagues represents a pivotal step in understanding the neuroprotective potential of Cistanche phelypaea fatty acids. Their findings not only enrich the existing literature on neurotrophic supplementation but also invigorate the discourse surrounding natural therapeutics in cognitive health. As research in this field progresses, there is hope that such natural compounds could become integral components of strategies aimed at mitigating the impact of neurodegenerative diseases and enhancing cognitive well-being.

While the present study is promising, it is crucial to keep in mind the broader context of brain health. Lifestyle factors such as diet, exercise, and mental stimulation consistently demonstrate their significance in supporting cognitive function. Integrating natural supplements with a holistic approach to brain health may provide the best outcomes for individuals looking to maintain cognitive vitality throughout their lives. Research like that conducted by Aboubaker et al. plays a vital role in directing attention to natural solutions, encouraging both scientific inquiry and public awareness of the potential benefits of herbal supplements.

Subject of Research: The effects of Cistanche phelypaea fatty acids as a natural neurotrophic supplement.

Article Title: Author Correction: Introduction of Cistanche phelypaea fatty acids as a new natural neurotrophic supplement by evaluating its effects in normal and Alzheimer’s diseased rats.

Article References:

Aboubaker, D.H., Elsayed, A.A.A., El-Gohary, A. et al. Author Correction: Introduction of Cistanche phelypaea fatty acids as a new natural neurotrophic supplement by evaluating its effects in normal and Alzheimer’s diseased rats. Sci Rep 15, 45801 (2025). https://doi.org/10.1038/s41598-025-34156-3

Image Credits: AI Generated

DOI: 10.1038/s41598-025-34156-3

Keywords: Cistanche phelypaea, fatty acids, neurotrophic supplement, Alzheimer’s disease, cognitive function.

Tags: Alzheimer’s disease treatment researchbioactive compounds for neuronal healthCistanche phelypaea fatty acidscognitive enhancement through supplementsdietary supplements for brain regenerationfatty acids and neuronal survivalnatural compounds for brain healthneuroprotective properties of herbal remediesneurotrophic supplements for cognitive functionOrobanchaceae family medicinal usestherapeutic potential of Cistanchetraditional medicine and modern science

Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.

The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.

The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.

There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.

GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.

• Our writers’ share tips for 2026, plus last year’s winners and losers

Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.

M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.

Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.

“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important.

“These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”

Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.

The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.

While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.

Marks & Spencer is launching a range of foods tailored to people taking weight-loss injections as use of the drugs accelerates in the UK.

The new range of 20 “nutrient-dense” products from the retailer is aimed at customers taking GLP-1 weight-loss medications, as supermarkets increasingly adapt to the impact the drugs are having on shopping baskets.

The range will go on sale in M&S foodhalls from January 5 and includes salads, meals and bread designed to deliver high levels of fibre, vitamins and minerals in smaller portions.

There has been a dramatic rise in the use of GLP-1 drugs in the UK. Online searches and private prescriptions have increased sharply, driven by their effectiveness for weight loss and widespread media attention. About 1.5 million people in the UK are now estimated to be accessing GLP-1 treatment privately, while NHS England prescriptions for the injections have risen by around 900 per cent since 2020.

GLP-1 medications — known formally as glucagon-like peptide-1 (GLP-1) receptor agonists — were originally developed to treat type 2 diabetes by helping to regulate blood sugar. In recent years, drugs such as semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro) have surged in popularity for their weight-loss effects, as they suppress appetite, slow digestion and signal fullness to the brain.

• Our writers’ share tips for 2026, plus last year’s winners and losers

Nutrient-dense foods are those that provide a concentrated source of vitamins, minerals, fibre, healthy fats and protein relative to their calorie content. M&S said the range was developed by its nutritionists in consultation with the British Nutrition Foundation, using criteria that ensure each product delivers more nutrients per mouthful.

M&S said the new range had been developed to address the nutritional challenges that can arise when people eat less, whether due to medication, age or lifestyle. A reduced appetite can make it harder to consume enough fibre and essential nutrients, increasing the risk of deficiencies and digestive side effects such as constipation.

Grace Ricotti, M&S head of food nutrition, said: “Our nutrient-dense range is perfect for customers looking to support their health as each recipe is packed with the key nutrients we all need in our diets.

“With the increase in popularity of weight-loss injections, a reduced appetite can mean missing out on important nutrients and that’s why nutrient density is so important.

“These new meals, snacks and drinks can help everyone get more fibre, vitamins and minerals in their diet.”

Supermarkets and consumer goods companies are increasingly catering to households using the drugs. Morrisons was the first UK supermarket to announce a dedicated “GLP-1 friendly” range, developed with sports nutrition brand Applied Nutrition, under its “Small & Balanced” banner. Nestlé, the consumer goods giant, has launched a frozen food brand in the US aimed at GLP-1 users, while Haleon, the British multinational consumer healthcare company, has introduced a multivitamin designed to help replenish nutrients for people eating less.

The trend is expected to accelerate further as GLP-1 medications move beyond injections. Tablet versions are beginning to reach the market, with US regulators approving an oral version of Wegovy and rival pills expected to follow, potentially widening access to the drugs.

While the drugs are approved for diabetes and obesity treatment, clinicians have raised concerns about the number of people accessing them outside clinical pathways for cosmetic weight loss. The long-term consequences of widespread use are still being studied, particularly as lower calorie intake can increase the risk of nutrient deficiencies if diets are not carefully managed.